Q1 FY2026 · ended Mar 31, 2026 · Revenue $25.56M, -8.0% YoY · Filed May 12, 2026
Anaptysbio, Inc. (ANAB) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q1 of fiscal 2026, the quarter ended Mar 31, 2026, it reported revenue of $25.6 million and a net loss of $52.9 million. Free cash flow was -$25.9 million. As of Jun 30, 2026 it held $164.1 million in cash and investments and $13.1 million in total debt.
Revenue
$25.56M
-8.0% vs year-ago quarter
Net income
$-52.88M
-34.5% vs year-ago quarter
Operating cash flow
$-25.92M
-142.2% vs year-ago quarter
Free cash flow
$-25.94M
-141.6% vs year-ago quarter
EPS
$-1.84
-43.8% vs year-ago quarter
Dividend per share
None
Shares outstanding
29.90M
+2.7% vs year-ago quarter
Net cash
$151.05M
Q4 FY2026
Operating margin
94.6%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ANAB (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1370053
- Former names
- ANAPTYSBIO INC (until Jun 12, 2019); ANAPTYS BIOSCIENCES INC (until Nov 20, 2007)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
Q1 FY2025 Mar 31, 2025 |
|---|---|---|---|---|---|
| Revenue | $25.6M | $108.2M | $76.3M | $22.3M | $27.8M |
| Operating income | -$34.6M | $245.9M | $34.7M | -$26.2M | -$27.5M |
| Net income | -$52.9M | $49.6M | $15.1M | -$38.6M | -$39.3M |
| Diluted EPS | -$1.84 | $1.48 | $0.52 | -$1.34 | -$1.28 |
| Operating cash flow | -$25.9M | $98.0M | -$27.4M | -$40.2M | -$10.7M |
| Free cash flow | -$25.9M | $98.0M | -$27.4M | -$40.3M | -$10.7M |
| Total assets | $329.7M | $364.4M | $353.1M | $335.2M | $422.1M |
| Stockholders' equity | $12.7M | $37.2M | -$29.4M | -$44.7M | $34.0M |
| Cash and investments | $286.5M | $211.6M | $256.7M | $293.7M | $383.0M |
| Total debt | $13,613 | $14,112 | $14.6M | $15.1M | $15.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-KT | Transition report | Sep 21, 2026 | Jun 30, 2026 |
| 8-K | Current report | Sep 21, 2026 | Sep 21, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 30, 2026 | Jul 28, 2026 |
| ARS | Annual report to shareholders | Jun 29, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Material agreement
|
Jun 22, 2026 | Jun 15, 2026 |
All 725 Anaptysbio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.